Advertisement

Pharmacy World and Science

, Volume 27, Issue 1, pp 20–30 | Cite as

Pharmacogenetics as a tool in the therapy of schizophrenia

  • Bob WilffertEmail author
  • Rianne Zaal
  • Jacobus R.B.J. Brouwers
Article

Abstract

Aim: This review summarises the present knowledge of associations between pharmacogenetics and therapeutic efficacy and side effects of antipsychotics to enable pharmacists to judge the applicability for a more tailor made therapy in patients with schizophrenia. Polymorphisms of Cytochrome P450 isoenzymes and neurotransmitter receptors involved in the efficacy and side effects of antipsychotics are highlighted in this review.

Method: A search was performed in Medline and EMBASE for the period 1995–August 2002. Also relevant references from the selected papers were incorporated.

Results: Poor metabolism with respect to CYP2D6 seems to be related with more pronounced extrapyramidal symptoms and more specifically with a higher incidence of tardive dyskinesia. The C/C-genotype for CYP1A2 results in smokers in a reduction of enzyme activity, but an effect on the incidence of tardive dyskinesia is controversial.

For dopamine D2 receptors the effect of the –141C Ins/ Del polymorphism on efficacy is not clear yet, although the Taq I polymorphism is associated with greater improvement of positive, but not negative symptoms in acute psychosis. The Gly9-allele of the dopamine D3 receptor is associated with the response to clozapine, but in studies in which the choice of antipsychotics is not restricted, the role of this polymorphism is unclear. The reverse is applicable to the dopamine D4.2/4.7 polymorphism.

For the 5-HT2A receptor the His452Tyr polymorphism is associated with response to clozapine, the 102 T/C polymorphism leads to equivocal results.

The polymorphism studied for 5-HT5A, 5-HT6, α1A- and α2A-receptors give no clear associations with the response to clozapine.

The polymorphism studied of the dopamine D2 and D4 receptor are not related to extrapyramidal adverse effects and side effects, respectively. The 9Gly-variant of the dopamine D3 receptor, the 102C-variant, but not the His452Tyr polymorphism of the 5-HT2A-receptor and the 23Ser-variant (for females only) of the 5-HT2C receptor seem to increase the susceptibility to tardive dyskinesia. Weight gain induced by antipsychotics seems to be associated with the –759C-allele of the 5-HT2C receptor.

Conclusion: The results show the first careful steps toward application of pharmacogenetics in a more individualised, tailor-made, pharmacotherapy. A precondition seems to be a multifactorial approach, as can be expected for multifactorial processes.

Keywords

Antipsychotics Atypical antipsychotics Cytochrome P450 isoenzymes Literature review Pharmacogenetics Receptor polymorphism Schizophrenia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Psychiatric Association1994Diagnosis and statistical manual of mental disdorders4American Psychiatric AssociationWashington DCGoogle Scholar
  2. Özdemir, V, Basile, VS, Masellis, M, Kennedy, JL 2001Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes.J Biochem Biophys Methods471517CrossRefPubMedGoogle Scholar
  3. Kawanishi, Y, Tachikawa, H, Suzuki, T 2000Pharmacogenomics and schizophrenia.Eur J Pharmacol41022741CrossRefPubMedGoogle Scholar
  4. Dahl, ML 2002Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics.Useful aid to prescribing? Clin Pharmacokinetics4145370Google Scholar
  5. Basile, VS, Masellis, M, McIntyre, RS, Meltzer, HY, Lieberman, JA, Kennedy, JL 2001Genetic dissection of atypical antipsychotic- induced weight gain: novel preliminary data on the pharmacogenetic puzzle.J Clin Psychiatry62(Suppl 23)4566Google Scholar
  6. Touw, DJ, Breimer, DD 1997Het cytochrome P450-enzymsysteem. Een familie met acties, reacties en interacties. Deel 1.Pharmaceutisch Weekblad13294863Google Scholar
  7. Touw, DJ, Breimer, DD 1997Het cytochrome P450-enzymsysteem. Een familie met acties, reacties en interacties. Deel 2.Pharmaceutisch Weekblad1329961009Google Scholar
  8. Staddon, S, Arranz, MJ, Mancama, D, Mata, I, Kerwin, RW 2002Clinical application of pharmacogenetics in psychiatry.Psychopharmacology1621823CrossRefPubMedGoogle Scholar
  9. Kirchheiner, J, Børsen, K, Dahl, ML, Gram, LF, Kasper, S, Roots, I,  et al. 2001CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.Acta Psychiatrica Scand10417392CrossRefGoogle Scholar
  10. Rijcken, CAW, Monster, TB, Brouwers, JRBJ, De Jong-van den Berg, LTW 2003Chlorpromazine equivalents versus Daily Defined Dose: how to compare antipsychotic drug dose?J Clin Psychopharmacol2365759CrossRefPubMedGoogle Scholar
  11. Wilson, JF, Weale, ME, Smith, AC, Gratrix, F, Fletcher, B, Thomas, MG,  et al. 2002Population genetic structure of variable drug response.Nat Genet2926569CrossRefGoogle Scholar
  12. Schulze, TG, Schumacher, J, Müller, DJ, Krauss, H, Alfter, D, Maroldt, A,  et al. 2001Lack of association between a functional polymorphism of the cytochrome P450 1A2(CYP1A2) gene and tardive dyskinesia in schizophrenia.Am J Med Genet105498501CrossRefPubMedGoogle Scholar
  13. Sachse, C, Brockmöller, J, Bauer, S, Roots, I 1999Functional significance of a C-A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine.Br J Clin Pharmacol4744549CrossRefPubMedGoogle Scholar
  14. Hughes, JR, Hatsukami, DK, Mitchell, JE, Dahlgren, LA 2004Prevalence of smoking among psychiatric outpatients.Am J Psychiatry1439937Google Scholar
  15. Lohr, JB, Flynn, K 1992Smoking and schizophrenia.Schizophrenia Res893102CrossRefGoogle Scholar
  16. Tauscher, J, Kapur, S 2001Choosing the right dose of antipsychotics in schizophrenia.Lessons from neuroimaging studies. CNS Drugs1567178Google Scholar
  17. Seeman, P, Tallerico, T 1998Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.Mol Psychiatry312334CrossRefPubMedGoogle Scholar
  18. Arinami, MJ, Gao, M, Hamaguchi, H, Toru, M 1997A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia.Human Mol Genet657782CrossRefGoogle Scholar
  19. Jönsson, E, Nöthen, MM, Grünhage, F, Farde, L, Nakashima, Y, Propping, P,  et al. 1996Polymorphisms in the dopamine D2 receptor gene and their relationship to striatal dopamine receptor density of healthy volunteers.Mol Psychiatry42906CrossRefGoogle Scholar
  20. Noble, EP, Blum, K, Ritchie, T, Montgomery, A, Sheridan, PJ 1991Allelic association of the D2 dopamine receptor gene with receptor binding characteristics in alcoholism.Arch Gen Psychiatry4864854PubMedGoogle Scholar
  21. Lundstrom, K, Turpin, MP 1996Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest Virus system.Biochem Biophys Res Commun225106872CrossRefPubMedGoogle Scholar
  22. Gaitonde, EJ, Morris, A, Sivagnanasundaram, S, McKenna, PJ, Hunt, DM, Mollon, JD 1996Assessment of association of D3 dopamine receptor MscI polymorphism with schizophrenia: analysis of symptom ratings, family history, age at onset, and movement disorders.Am J Genet (Neuropsychiatric Genetics)674558CrossRefGoogle Scholar
  23. Scharfetter, J, Chaudry, HR, Hornik, K, Fuchs, K, Sieghart, W, Kasper, S,  et al. 1999Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients.Eur Neuropsychopharmacol101720CrossRefPubMedGoogle Scholar
  24. Tol, H, Wu, CM, Guan, H-C, Ohara, K, Bunzow, JR, Civelli, O,  et al. 1992Multiple dopamine D4 receptor variants in the human population.Nature35814952CrossRefPubMedGoogle Scholar
  25. O’Dowd, BF 1992Repeat sequences in the gene encoding the human D4 dopamine receptor.Gene1183012CrossRefPubMedGoogle Scholar
  26. Ashgari, V, Sanyal, S, Buchwaldt, S, Paterson, A, Jovanovic, V, Tol, H 1995Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants.J Neurochem65115765PubMedGoogle Scholar
  27. Baldessarini, RJ, Frankenburg, FR 1991Clozapine- a novel antipsychotic agent.New Engl J Med32474654PubMedGoogle Scholar
  28. Leysen, JE, Janssen, PMF, Heylen, L, Gommeren, W, Gompel, Pv, Lesage, AS,  et al. 1998Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects.Int J Psychiatry Clin Prac2S3S17Google Scholar
  29. Busatto, GF, Kerwin, RW 2002Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia.J Psychopharmacol11312Google Scholar
  30. Arranz, MJ, Munro, J, Sham, P, Kirov, G, Murray, RM, Collier, DA,  et al. 1998Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.Schizophrenia Res32939CrossRefGoogle Scholar
  31. Masellis, M, Basile, VS, Meltzer, HY, Lieberman, JA, Sevy, S, Macciardi, FM,  et al. 1998Serotonin Subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.Neuropsychopharmacology1912332CrossRefPubMedGoogle Scholar
  32. Sodhi, MS, Murray, RM 1997Future therapies for schizophrenia.Expert Opin Ther Patents715165Google Scholar
  33. Mihara, K, Kondo, T, Suzuki, A, Yasui, N, Ono, S, Otani, K,  et al. 2001No relationship between -141C Ins/Del polymorphism in the promotor region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study.Psychiatry Res101338CrossRefPubMedGoogle Scholar
  34. Mihara, K, Suzuki, A, Kondo, T, Nagashima, U, Oho, S, Otani, K,  et al. 2000No relationship between Taq1 A polymorphism of dopamine D-2 receptor gene and extrapyramidal adverse effects of selective dopamine D-2 antagonists, bromperidol, and nemonapride in schizophrenia: A preliminary study.Am J Med Genet964224CrossRefPubMedGoogle Scholar
  35. Lerer, B, Segman, RH, Fangerau, H, Daly, AK, Basile, VS, Cavallaro, R,  et al. 2002Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism.Neuropsychopharmacology2710519CrossRefPubMedGoogle Scholar
  36. Tan, E-C, Chong, S-A, Mahendran, R, Dong, F, Tan, CH 2001Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor.Biol Psychiatry501447CrossRefPubMedGoogle Scholar
  37. Bannon, MJ, Granneman, JG, Kapatos, G 1995The dopamine transporter: potential involvement in neuropsychiatric disorders.Bloom, FEKupfer, DJ eds. Psychopharmacology 4th generation of progress.Raven PressNew York17988Google Scholar
  38. Segman, RH, Heresco-Levy, U, Finkel, B, Inbar, R, Neeman, T, Schlafman, M,  et al. 2000Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility.Psychopharmacology15240813CrossRefPubMedGoogle Scholar
  39. Yu, YWY, Tsai, SJ, Lin, CH, Hsu, CP, Ynakg, KH, Hong, CJ 1999Serotonin-6 receptor variant (C267T) and clinical response to clozapine.Neuroreport1012313PubMedGoogle Scholar
  40. Masellis, M, Basile, VS, Meltzer, HY, Lieberman, JA, Sevy, S, Goldman, DA,  et al. 2001Lack of association between the T/C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia.Schizophrenia Res474958CrossRefGoogle Scholar
  41. Arranz, MJ, Munro, J, Birkett, J, Bolonna, A, Mancama, D, Sodhi, M,  et al. 2000Pharmacogenetic prediction of clozapine response.Lancet35516156CrossRefPubMedGoogle Scholar
  42. Arranz, MJ, Staddon, S, Mancama, D, Munro, J, Osborne, S, Beperet, M,  et al. 2001Response to olanzapine influenced by genes in neurotransmitter receptors.Am J Human Genet692933Google Scholar
  43. Joober, R, Benkelfat, C, Brisebois, K, Toulouse, A, Turecki, G, Lal, S,  et al. 1999T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability.J Psychiatry Neurosci241416PubMedGoogle Scholar
  44. Ohara, K, Nagai, M, Tani, K, Nakamura, Y, Ino, A 1998Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia.Psychiatry Res8111723CrossRefPubMedGoogle Scholar
  45. Schäfer, M, Rujescu, D, Giegling, I, Guntermann, A, Erfurth, A, Bondy, B,  et al. 2001Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D2 receptor gene.Am J Psychiatry1588024CrossRefPubMedGoogle Scholar
  46. Scordo, MG, Spina, E, Romeo, P, Dahl, ML, Bertilsson, L, Johansson, I,  et al. 2000CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.Eur J Clinical Pharmacology5667983CrossRefGoogle Scholar
  47. Kapitany, T, Meszaros, K, Lenzinger, E, Schindler, SD, Barnas, C, Fuchs, K,  et al. 1998Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.Schizophrenia Res321016CrossRefGoogle Scholar
  48. Tamminga, WJ, Wemer, J, Oosterhuis, B, Boer, A, Vranckx, S, Drenth, BFH,  et al. 2003Polymorphic drug metabolism (CYP2D6) and utilization of psychotropic drugs in hospitalised psychiatric patients–a retrospective study.Eur J Clin Pharmacol595764PubMedGoogle Scholar
  49. Basile, VS, Özdemir, V, Masellis, M, Walker, ML, Meltzer, HY, Lieberman, JA,  et al. 2000A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia.Mol Psychiatry54107CrossRefPubMedGoogle Scholar
  50. Arranz, MJ, Li, T, Munro, J, Liu, X, Murray, R, Collier, DA,  et al. 1998Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response.Pharmacogenetics84814PubMedGoogle Scholar
  51. Malhotra, AK, Buchanan, RW, Kim, S, Kestler, L, Breier, A, Pickar, D,  et al. 1999Allelic variation in the promoter region of the dopamine D2 receptor gene and clozapine response.Schizophrenia Res36923Google Scholar
  52. Suzuki, A, Mihara, K, Kondo, T, Tanaka, O, Nagashima, U, Otani, K,  et al. 2000The relationship between dopamine D2 receptor polymorphism at the Taq I A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients.Pharmacogenetics200033541CrossRefGoogle Scholar
  53. Ebstein, RP, Macciardi, F, Heresco-Levy, U, Serretti, A, Blaine, D, Verga, M,  et al. 1997Evidence for an association between the dopamine D3 receptor gene DRD3 and schizophrenia.Human Hered47616Google Scholar
  54. Shaikh, S, Collier, DA, Sham, PC, Ball, D, Aitchison, K, Vallada, H,  et al. 1996Allelic association between Ser-9-Gly polymorphisms in the dopamine D3 receptor gene and schizophrenia.Human Genet977149CrossRefGoogle Scholar
  55. Malhotra, AK, Goldman, D, Buchanan, RW, Rooney, W, Clifton, A, Kosmidis, MH,  et al. 1998The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.Mol Psychiatry3725CrossRefPubMedGoogle Scholar
  56. Durany, N, Thome, J, Palomo, A, Foley, P, Riederer, P, Cruz-Sanchez, FF 1996Homozygosity at the dopamine D3 receptor gene in schizophrenic patients.Neurosci Lett2201514CrossRefPubMedGoogle Scholar
  57. Krebs, MO, Sautel, F, Bourdel, M-C, Sokoloff, P, Schwartz, J-C, Lôo, H,  et al. 1998Dopamine D3 receptor gene variants and substance abuse in schizophrenia.Mol Psychiatry333741CrossRefPubMedGoogle Scholar
  58. Joober, R, Toulouse, A, Benkelfat, C, Lal, S, Bloom, D, Labelle, A,  et al. 2000DRD3 and DAT1 genes in schizophrenia: an association study.J Psychiatric Res3428591CrossRefGoogle Scholar
  59. Kennedy, JL, Billet, EA, Macciardi, FM, Verga, M, Parsons, TJ, Meltzer, HY,  et al. 1995Association study of dopamine D3 receptor gene and schizophrenia.Am J Med Genet (Neuropsychiatric Genetics)6055862Google Scholar
  60. Cohen, BM, Ennulat, DJ, Centorrino, F, Matthysse, S, Konieczna, H, Chu, HM,  et al. 1999Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs.Psychopharmacology (Berl)141610CrossRefGoogle Scholar
  61. Hwu, HG, Hong, CJ, Lee, YL, Lee, PC, Lee, SFC 1998Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia.Biol Psychiatry444837CrossRefPubMedGoogle Scholar
  62. Shaikh, S, Collier, D, Kerwin, R, Pilowski, LS, Gill, M, Xu, W-M,  et al. 1993Dopamine D4 receptor subtypes and response to clozapine.Lancet341116CrossRefGoogle Scholar
  63. Rao, PA, Pickar, D, Gejman, PV, Ram, A, Gershon, ES, Gelernter, J 1994Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine.Arch Gen Psychiatry519127PubMedGoogle Scholar
  64. Rietschel, M, Naber, D, Oberländer, H, Holzbach, R, Fimmers, R, Eggerman, K,  et al. 1996Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene.Neuropsychopharmacology154916CrossRefPubMedGoogle Scholar
  65. Özdemir, V, Masellis, M, Basile, VS, Kalow, W, Meltzer, HY, Lieberman, JA,  et al. 1999Variability in response to clozapine: potential role of cytochrome P450 1A2 and the dopamine D4 receptor gene.CNS Spectr43056Google Scholar
  66. Arranz, M, Collier, D, Sodhi, M, Ball, D, Roberts, G, Price, J,  et al. 1995Association between clozapine response and allelic variation in 5-HT2A receptor gene.Lancet3462812CrossRefPubMedGoogle Scholar
  67. Arranz, MJ, Collier, DA, Munro, J, Sham, P, Kirov, G, Sodhi, M,  et al. 1996Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine.Neurosci Lett2171778CrossRefPubMedGoogle Scholar
  68. Malhotra, AK, Goldman, D, Ozaki, N, Breier, A, Buchanan, RW, Pickar, D 1996Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine.Am J Psychiatry15310924PubMedGoogle Scholar
  69. Birkett, JT, Arranz, MJ, Munro, J, Osbourn, S, Kerwin, RW, Collier, D 2000Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response.Neuroreport11201720PubMedGoogle Scholar
  70. Bolonna, AA, Arranz, MJ, Munro, J, Osborne, S, Petouni, M, Martinez, M,  et al. 2000No influence of adrenergic receptor polymorphism on schizophrenia and antipsychotic response.Neurosci Lett280658CrossRefPubMedGoogle Scholar
  71. Kaiser, R, Klufmöller, F, Roots, I, Brockmöller, J 2002Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphisms in patients with schizophrenia.Mol Psychiatry7695705CrossRefPubMedGoogle Scholar
  72. Chen, C-H, Wei, F-C, Koong, F-J, Hsiao, K-J 1997Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia.Biol Psychiatry418279CrossRefPubMedGoogle Scholar
  73. Segman, R, Neeman, T, Heresco-Levy, U, Finkel, B, Karagichev, L, Schlafman, M,  et al. 1999Genotypic association between dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia.Mol Psychiatry424753CrossRefPubMedGoogle Scholar
  74. Steen, VM, Lovlie, R, MacEwan, T, McCreadie, RG 1997Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients.Mol Psychiatry213945CrossRefPubMedGoogle Scholar
  75. Rietschel, M, Kraus, H, Muller, DJ, Schulze, TG, Knapp, M, Marwinski, K,  et al. 2000Dopamine D3 receptor variant and tardive dyskinesia.Eur Arch Psychiatry Clin Neurosci250315PubMedGoogle Scholar
  76. Liao, DL, Yeh, YC, Chen, HM, Chen, H, Hong, CJ, Tsai, SJ 2001Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients.Neuropsychobiology44958CrossRefPubMedGoogle Scholar
  77. Garcia-Barcelo, MM, Lam, LC, Ungvari, GS, Lam, VK, Tang, WK 2001Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients.J Neural Transm1086717CrossRefPubMedGoogle Scholar
  78. Chong, S-A, Tan, E-C, Tan, CH, Mythily, , Chan, YH 2003Polymorphisms of dopamine receptors and tardive dykinesia among Chinese patients with schizophrenia.Am J Med Genet116(1 Suppl)514CrossRefGoogle Scholar
  79. Segman, RH, Heresco-Levy, U, Finkel, B, Goltser, T, Shalem, R, Schlafman, M,  et al. 2001Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.Mol Psychiatry62259CrossRefPubMedGoogle Scholar
  80. Reynolds, GP, Zhang, Z-J, Zhang, X-B 2002Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism.Lancet35920867CrossRefPubMedGoogle Scholar
  81. Basile, VS, Masellis, M, Potkin, SG, Kennedy, JL 2002Pharmacogenomics in schizophrenia: the quest for individualized therapy.Human Mol Genet11251730CrossRefGoogle Scholar
  82. Lüllmann, H, Mohr, K, Ziegler, A, Bieger, D 2000Color atlas of pharmacology2Georg Thieme VerlagStuttgart,GermanyGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Bob Wilffert
    • 1
    • 2
    Email author
  • Rianne Zaal
    • 3
  • Jacobus R.B.J. Brouwers
    • 3
    • 4
  1. 1.Rheinische Friedrich-Wilhelms-UniversitätBonnGermany
  2. 2.Department of Clinical Pharmacy of Zorggroep Noorderbreedte-and De TjongerschansLeeuwardenThe Netherlands
  3. 3.Department of Social Pharmacy, Pharmacoepidemiology & PharmacotherapyGroningen University Institute for Drug Exploration (GUIDE)GroningenThe Netherlands
  4. 4.Department of Clinical Pharmacy of Zorggroep Noorderbreedte and De TjongerschansLeeuwardenThe Netherlands

Personalised recommendations